Clinical Significance of ADAMTS19, BMP7, SIM1, and SFRP1 Promoter Methylation in Renal Clear Cell Carcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68(1):7–30. doi:10.3322/caac.21442
   PubMed Web of Science ®Google Scholar
• Chow WH, Dong LM, Devesa SS. Epidemiology and risk factors for kidney cancer. Nat Rev Urol. 2010;7(5):245–257. doi:10.1038/nrurol.2010.46
   PubMed Web of Science ®Google Scholar
• Capitanio U, Bensalah K, Bex A, et al. Epidemiology of renal cell carcinoma. Eur Urol. 2019;75(1):74–84. doi:10.1016/j.eururo.2018.08.036
   PubMed Web of Science ®Google Scholar
• Dabestani S, Thorstenson A, Lindblad P, Harmenberg U, Ljungberg B, Lundstam S. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a Population-Based Study. World J Urol. 2016;34(8):1081–1086. doi:10.1007/s00345-016-1773-y
   PubMed Web of Science ®Google Scholar
• Padala SA, Barsouk A, Thandra KC, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79–87. doi:10.14740/wjon1279
   PubMedGoogle Scholar
• Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol. 2001;166(1):63–67. doi:10.1016/S0022-5347(05)66077-6
   PubMed Web of Science ®Google Scholar
• Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. An outcome prediction model for patients with clear cell renal cell carcinoma treated with radical nephrectomy based on tumor stage, size, grade and necrosis: the SSIGN score. J Urol. 2002;168(6):2395–2400. doi:10.1016/S0022-5347(05)64153-5
   PubMed Web of Science ®Google Scholar
• Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol. 2001;19(6):1649–1657. doi:10.1200/JCO.2001.19.6.1649
   PubMed Web of Science ®Google Scholar
• Wei JH, Haddad A, Wu KJ, et al. A CpG-methylation-based assay to predict survival in clear cell renal cell carcinoma. Identification of a five-CpG-based classifier that has added prognostic value to the currently used staging system and risk scores, and could thus be of high clinical value. Nat Commun. 2015;6:8699.
   PubMed Web of Science ®Google Scholar
• Hurtado Del Pozo C, Garreta E, Izpisúa Belmonte JC, Montserrat N. Modeling epigenetic modifications in renal development and disease with organoids and genome editing. Dis Model Mech. 2018;11(11):dmm035048. doi:10.1242/dmm.035048
   PubMed Web of Science ®Google Scholar
• Wu P, Cao Z, Wu S. New progress of epigenetic biomarkers in urological cancer. Dis Markers. 2016;2016:9864047. doi:10.1155/2016/9864047
   PubMed Web of Science ®Google Scholar
• Shenoy N, Vallumsetla N, Zou Y, et al. Role of DNA methylation in renal cell carcinoma. J Hematol Oncol. 2015;8(1):88. doi:10.1186/s13045-015-0180-y
   PubMedGoogle Scholar
• Arai E, Kanai Y. Genetic and epigenetic alterations during renal carcinogenesis. Int J Clin Exp Pathol. 2010;4(1):58–73.
   PubMed Web of Science ®Google Scholar
• Minardi D, Lucarini G, Filosa A, et al. Prognostic role of global DNA-methylation and histone acetylation in pT1a clear cell renal carcinoma in partial nephrectomy specimens. J Cell Mol Med. 2009;13(8B):2115–2121. doi:10.1111/j.1582-4934.2008.00482.x
   PubMed Web of Science ®Google Scholar
• Morris MR, Latif F. The epigenetic landscape of renal cancer. Nat Rev Nephrol. 2017;13(1):47–60.
   PubMed Web of Science ®Google Scholar
• Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499(7456):43–49. doi:10.1038/nature12222
   PubMed Web of Science ®Google Scholar
• Maleckaite R, Zalimas A, Bakavicius A, Jankevicius F, Jarmalaite S, Daniunaite K. DNA methylation of metallothionein genes is associated with the clinical features of renal cell carcinoma. Oncol Rep. 2019;41(6):3535–3544.
   PubMed Web of Science ®Google Scholar
• Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours, 7th edition. Cancer. 2009;7:310.
   Google Scholar
• Lopez-Beltran A, Scarpelli M, Montironi R, Kirkali Z. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798–805. doi:10.1016/j.eururo.2005.11.035
   PubMed Web of Science ®Google Scholar
• Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655–663. doi:10.1097/00000478-198210000-00007
   PubMed Web of Science ®Google Scholar
• Delahunt B, Cheville JC, Martignoni G, et al. The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol. 2013;37(10):1490. doi:10.1097/PAS.0b013e318299f0fb
   PubMed Web of Science ®Google Scholar
• Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.21492
   PubMed Web of Science ®Google Scholar
• Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an International Multicenter Study. J Clin Oncol. 2004;22(16):3316–3322. doi:10.1200/JCO.2004.09.104
   PubMed Web of Science ®Google Scholar
• Zigeuner R, Hutterer G, Chromecki T, et al. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology. Eur Urol. 2010;57(1):102–109. doi:10.1016/j.eururo.2008.11.033
   PubMed Web of Science ®Google Scholar
• Ibragimova I, Slifker MJ, Maradeo ME, et al. Genome-wide promoter methylome of small renal masses. PLoS One. 2013;8(10):e77309. doi:10.1371/journal.pone.0077309
   PubMed Web of Science ®Google Scholar
• Kang HW, Park H, Seo SP, et al. Methylation signature for prediction of progression free survival in surgically treated clear cell renal cell carcinoma. J Korean Med Sci. 2019;34(19):e144. doi:10.3346/jkms.2019.34.e144
   PubMed Web of Science ®Google Scholar
• Kim YJ, Jang W, Piao XM, et al. ZNF492 and GPR149 methylation patterns as prognostic markers for clear cell renal cell carcinoma: array-based DNA methylation profiling. Oncol Rep. 2019;42(1):453–460.
   PubMed Web of Science ®Google Scholar
• Yoo KH, Park YK, Kim HS, Jung WW, Chang SG. Epigenetic inactivation of HOXA5 and MSH2 gene in clear cell renal cell carcinoma. Pathol Int. 2010;60(10):661–666. doi:10.1111/j.1440-1827.2010.02578.x
   PubMed Web of Science ®Google Scholar
• Ricketts CJ, Morris MR, Gentle D, et al. Genome-wide CpG island methylation analysis implicates novel genes in the pathogenesis of renal cell carcinoma. Epigenetics. 2012;7(3):278–290. doi:10.4161/epi.7.3.19103
   PubMed Web of Science ®Google Scholar
• van Vlodrop IJH, Joosten SC, De Meyer T, et al. Four-gene promoter methylation marker panel consisting of GREM1, NEURL, LAD1, and NEFH predicts survival of clear cell renal cell cancer patients. Clin Cancer Res. 2017;23(8):2006–2018. doi:10.1158/1078-0432.CCR-16-1236
   PubMed Web of Science ®Google Scholar
• Dagher J, Delahunt B, Rioux-Leclercq N, et al. Assessment of tumour-associated necrosis provides prognostic information additional to World Health Organization/International Society of Urological Pathology grading for clear cell renal cell carcinoma. Histopathology. 2019;74(2):284–290. doi:10.1111/his.13737
   PubMed Web of Science ®Google Scholar
• Morris MR, Ricketts C, Gentle D, et al. Identification of candidate tumour suppressor genes frequently methylated in renal cell carcinoma. Oncogene. 2010;29(14):2104–2117. doi:10.1038/onc.2009.493
   PubMed Web of Science ®Google Scholar
• Ricketts CJ, Hill VK, Linehan WM. Tumor-specific hypermethylation of epigenetic biomarkers, including SFRP1, predicts for poorer survival in patients from the TCGA kidney renal clear cell carcinoma (KIRC) project. PLoS One. 2014;9(1):e85621. doi:10.1371/journal.pone.0085621
   PubMed Web of Science ®Google Scholar
• van Vlodrop IJ, Niessen HE, Derks S, et al. Analysis of promoter CpG island hypermethylation in cancer: location, location, location! Clin Cancer Res. 2011;17(13):4225–4231. doi:10.1158/1078-0432.CCR-10-3394
   PubMed Web of Science ®Google Scholar
• Turajlic S, Xu H, Litchfield K, et al. Deterministic evolutionary trajectories influence primary tumor growth: tRACERx renal. Cell. 2018;173(3):595–610. doi:10.1016/j.cell.2018.03.043
   PubMed Web of Science ®Google Scholar
• Brooks SA, Brannon AR, Parker JS, et al. ClearCode34: a prognostic risk predictor for localized clear cell renal cell carcinoma. Eur Urol. 2014;66(1):77–84. doi:10.1016/j.eururo.2014.02.035
   PubMed Web of Science ®Google Scholar
• Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol. 2015;16(6):676–685. doi:10.1016/S1470-2045(15)70167-1
   PubMed Web of Science ®Google Scholar
• Cal S, López-Otín C. ADAMTS proteases and cancer. Matrix Biol. 2015;44–46:77–85. doi:10.1016/j.matbio.2015.01.013
   PubMed Web of Science ®Google Scholar
• Hubmacher D, Apte SS. Genetic and functional linkage between ADAMTS superfamily proteins and fibrillin-1: a novel mechanism influencing microfibril assembly and function. Cell Mol Life Sci. 2011;68(19):3137–3148. doi:10.1007/s00018-011-0780-9
   PubMed Web of Science ®Google Scholar
• Zeisberg M. Bone morphogenic protein-7 and the kidney: current concepts and open questions. Nephrol Dial Transplant. 2006;21(3):568–573. doi:10.1093/ndt/gfk010
   PubMed Web of Science ®Google Scholar
• Gregory KE, Ono RN, Charbonneau NL, et al. The prodomain of BMP-7 targets the BMP-7 complex to the extracellular matrix. J Biol Chem. 2005;280(30):27970–27980. doi:10.1074/jbc.M504270200
   PubMed Web of Science ®Google Scholar
• Wang Z, Zhao J, Zhang J, Wei J, Huang Y, Huang Y. Protective effect of BMP-7 against aristolochic acid-induced renal tubular epithelial cell injury. Toxicol. Lett. 2010;198(3):348–357. doi:10.1016/j.toxlet.2010.07.018
   PubMed Web of Science ®Google Scholar
• Gould SE, Day M, Jones SS, Dorai H. BMP-7 regulates chemokine, cytokine, and hemodynamic gene expression in proximal tubule cells. Kidney Int. 2002;61(1):51–60. doi:10.1046/j.1523-1755.2002.00103.x
   PubMed Web of Science ®Google Scholar
• Basic-Jukic N, Hudolin T, Radic-Antolic M, et al. Bone morphogenetic protein-7 expression is down-regulated in human clear cell renal carcinoma. J Nephrol. 2011;24(1):91–97. doi:10.5301/JN.2010.2020
   PubMed Web of Science ®Google Scholar
• Pantuck AJ, An J, Liu H, Rettig MB. NF-κB–dependent plasticity of the epithelial to mesenchymal transition induced by Von Hippel-Lindau inactivation in renal cell carcinomas. Cancer Res. 2010;70(2):752–761. doi:10.1158/0008-5472.CAN-09-2211
   PubMed Web of Science ®Google Scholar
• Markić D, Celić T, Spanjol J, Grsković A, Bobinac D, Fuckar Z. Expression of bone morphogenetic protein-7, its receptors and Smad1/5/8 in normal human kidney and renal cell cancer. Coll Antropol. 2010;34(Suppl 2):149–153.
   PubMedGoogle Scholar
• Mo S, Su Z, Heng B, et al. SFRP1 promoter methylation and renal carcinoma risk: a systematic review and meta-analysis. J Nippon Med Sch. 2018;85(2):78–86. doi:10.1272/jnms.2018_85-13
   PubMed Web of Science ®Google Scholar
• Valenta T, Hausmann G, Basler K. The many faces and functions of β-catenin. EMBO J. 2012;31(12):2714–2736. doi:10.1038/emboj.2012.150
   PubMed Web of Science ®Google Scholar
• Atschekzei F, Hennenlotter J, Janisch S, et al. SFRP1 CpG island methylation locus is associated with renal cell cancer susceptibility and disease recurrence. Epigenetics. 2012;7(5):447–457. doi:10.4161/epi.19614
   PubMed Web of Science ®Google Scholar
• Michaud JL, Rosenquist T, May NR, Fan CM. Development of neuroendocrine lineages requires the bHLH-PAS transcription factor SIM1. Genes Dev. 1998;12:3264–3275. doi:10.1101/gad.12.20.3264
   PubMed Web of Science ®Google Scholar
• Kim MJ, Oksenberg N, Hoffmann TJ, Vaisse C, Ahituv N. Functional characterization of SIM1-associated enhancers. Hum Mol Genet. 2014;23(7):1700–1708. doi:10.1093/hmg/ddt559
   PubMed Web of Science ®Google Scholar
• Sidaway P. Kidney cancer: methylation of obesity-related genes is associated with prognosis. Nat Rev Urol. 2017;14(8):452. doi:10.1038/nrurol.2017.94
   PubMed Web of Science ®Google Scholar
• Faryna M, Konermann C, Aulmann S, et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 2012;26(12):4937–4950. doi:10.1096/fj.12-209502
   PubMed Web of Science ®Google Scholar
• Daugaard I, Dominguez D, Kjeldsen TE, et al. Identification and validation of candidate epigenetic biomarkers in lung adenocarcinoma. Sci Rep. 2016;6(1):35807. doi:10.1038/srep35807
   PubMedGoogle Scholar
• Kim HJ, Kim CY, Jin J, et al. Aberrant single-minded homolog 1 methylation as a potential biomarker for cervical cancer. Diagn Cytopathol. 2018;46(1):15–21. doi:10.1002/dc.23838
   PubMed Web of Science ®Google Scholar
• Sauerbrei W, Taube SE, McShane LM, Cavenagh MM, Altman DG. Reporting recommendations for tumor marker prognostic studies (REMARK): an abridged explanation and elaboration. J Natl Cancer Inst. 2018;110(8):803–811. doi:10.1093/jnci/djy088
   PubMedGoogle Scholar